Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression

(2013) Loredana Ciuclan et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

(2013) Rashmi R. Shah et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials

(2013) Guru Sonpavde et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Early Investigation of QTc Liability

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed

(2013) C. Guignabert et al.   EUROPEAN RESPIRATORY JOURNAL

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

(2012) Richard M. Steingart et al.   AMERICAN HEART JOURNAL

Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension

(2012) Soni Savai Pullamsetti et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis

(2012) Yamini Krishnan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Blocking of the Human Ether-^|^agrave;-go-go-Related Gene Channel by Imatinib Mesylate

(2012) Qian Dong et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

(2012) Rashmi R. Shah   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use

(2012) Constantin A Dasanu et al.   Expert Opinion On Drug Safety

Targeting PDGF pathway in pulmonary arterial hypertension

(2012) Sabina Antonela Antoniu   EXPERT OPINION ON THERAPEUTIC TARGETS

Clinical cardiac safety profile of nilotinib

(2012) T. D. Kim et al.   HAEMATOLOGICA

Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling

(2012) Baktybek Kojonazarov et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

(2012) Baichun Yang et al.   JOURNAL OF APPLIED TOXICOLOGY

Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

(2012) Fabio A.B. Schutz et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

(2012) Sophie Leboulleux et al.   LANCET ONCOLOGY

Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience

(2012) Erkan Dogan et al.   MEDICAL ONCOLOGY

hERG K+ Channels: Structure, Function, and Clinical Significance

(2012) Jamie I. Vandenberg et al.   PHYSIOLOGICAL REVIEWS

Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

(2012) Jiajie Zang et al.   PLoS One

Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome

(2012) Z. Lu et al.   Science Translational Medicine

The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients

(2012) Guru Sonpavde et al.   Current Oncology Reports

A Novel Murine Model of Severe Pulmonary Arterial Hypertension

(2011) Loredana Ciuclan et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

(2011) Jenny J. Kim et al.   CANCER

A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity

(2011) Hui Cheng et al.   CIRCULATION RESEARCH

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Matthias Scheffler et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

Imatinib mesylate for the treatment of pulmonary arterial hypertension

(2011) Henrik ten Freyhaus et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Protein Kinase A Activity at the Endoplasmic Reticulum Surface Is Responsible for Augmentation of Humanether-a-go-go-related Gene Product (HERG)

(2011) Jakub Sroubek et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

(2011) R. Dienstmann et al.   ONCOLOGIST

Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents

(2011) I. M. Subbiah et al.   ONCOLOGIST

Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review

(2011) D. Keefe et al.   ONCOLOGIST

Cardiovascular toxicity of anti-angiogenic drugs

(2011) Gaetan des Guetz et al.   Targeted Oncology

Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy

(2010) Hossein A. Ghofrani et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cardiovascular Side-Effects of Modern Cancer Therapy

(2010) Manabu Minami et al.   CIRCULATION JOURNAL

Introduction to Cardiotoxicity Review Series

(2010) Thomas Force   CIRCULATION RESEARCH

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

(2010) Thomas Eschenhagen et al.   EUROPEAN JOURNAL OF HEART FAILURE

Imatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial Hypertension

(2010) Masaru Hatano et al.   International Heart Journal

Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

(2010) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies

(2010) F. Girardi et al.   ONCOLOGIST

The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society

(2010) Daniel J. Lenihan et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?

(2010) Hui Cheng et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

(2010) Emily S. Robinson et al.   SEMINARS IN NEPHROLOGY

Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer

(2010) Howard R. Mellor et al.   TOXICOLOGICAL SCIENCES

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

(2010) Brian B. Hasinoff et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

(2010) Brian B. Hasinoff   TOXICOLOGY AND APPLIED PHARMACOLOGY

QTc shortening with a new investigational cancer drug: A brief case study

(2010) Herbert M. Himmel et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Assessing proarrhythmic potential of drugs when optimal studies are infeasible

(2009) Edwin P. Rock et al.   AMERICAN HEART JOURNAL

PKA phosphorylation of HERG protein regulates the rate of channel synthesis

(2009) Jian Chen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Hypertension as a surrogate marker for the activity of anti-VEGF agents

(2009) O. Mir et al.   ANNALS OF ONCOLOGY

Thrombosis associated with angiogenesis inhibitors

(2009) Francesca Elice et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

(2009) Brian B. Hasinoff et al.   Cardiovascular Toxicology

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

(2009) M. L. Maitland et al.   CLINICAL CANCER RESEARCH

Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)

(2009) J Morganroth et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

(2009) Henrik ten Freyhaus et al.   Clinical Research in Cardiology

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

(2009) Risto Kerkela et al.   CTS-Clinical and Translational Science

Cardiovascular toxicity of molecularly targeted agents

(2009) Elizabeth L. Strevel et al.   EUROPEAN JOURNAL OF CANCER

Gastrointestinal toxicities of novel agents in cancer therapy

(2009) Amani Asnacios et al.   EUROPEAN JOURNAL OF CANCER

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions

(2009) Hester van Cruijsen   Frontiers in Bioscience-Landmark

QT interval prolongation among patients treated with angiogenesis inhibitors

(2009) Stephane Ederhy et al.   Targeted Oncology

Portopulmonary Hypertension: Imatinib as a Novel Treatment and the Emory Experience With this Condition

(2009) E.B. Tapper et al.   TRANSPLANTATION PROCEEDINGS

Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels

(2008) De-Yong Zhang et al.   CELLULAR SIGNALLING

Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

(2008) Ming Hui Chen et al.   CIRCULATION

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

PDGF-B signaling is important for murine cardiac development: Its role in developing atrioventricular valves, coronaries, and cardiac innervation

(2008) Nynke M.S. Van den Akker et al.   DEVELOPMENTAL DYNAMICS

Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem

(2008) Thomas Force et al.   DRUG DISCOVERY TODAY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Concentration-QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review

(2007) Christin E. Garnett et al.   JOURNAL OF CLINICAL PHARMACOLOGY